Comphya

1. Executive Summary (Confidence: High)

Comphya SA, an EPFL spin-off based in Lausanne, is pioneering a paradigm shift in the treatment of erectile dysfunction (ED) by moving from compensatory therapies to nerve-restoring neuromodulation. Its flagship product, CaverSTIM, is an implantable pulse generator (IPG) that delivers direct electrical stimulation to the cavernous nerves responsible for penile erection. This technology is primarily aimed at the approximately 400,000 men who undergo radical prostatectomy each year in the U.S. and Europe, a large portion of whom suffer from long-term ED despite nerve-sparing surgical techniques. Comphya has successfully validated its technology through a first-in-man pilot study in Australia, which demonstrated a 90% erectile function recovery rate by nine months without safety concerns. The company is currently executing a global clinical development program, including an FDA-approved Investigational Device Exemption (IDE) study in the United States and trials in Brazil. With approximately $16. million in total funding and a recent Series A round, Comphya is positioned to introduce a smarter, integrated solution that fits directly into existing robotic surgical workflows.